AstraZeneca on Tuesday released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease, boosting hopes that it could generate multibillion-dollar sales for the company. The biologic medicine, tozorakimab, is under priority review by the Food and Drug Administration, with U.S. approval expected in the first quarter of 2027….
Blood sample for a lipoprotein(a) test. Md Babul Hosen | Istock | Getty Images Novartis‘ failure in a closely watched cardiovascular trial has raised questions about one of the pharmaceutical industry’s biggest drug races and rival treatments from U.S. heavyweights Amgen and Eli Lilly. The pelacarsen drug, developed jointly with Ionis Pharmaceuticals, reduced a particularly…
Stanley Druckenmiller at CNBC’s Delivering Alpha on Sept. 28, 2022. Scott Mlyn | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Investment firms of ultra-wealthy families are helping fuel the…
U.S. President Donald Trump delivers remarks on his administration’s healthcare policies, in the Oval Office at the White House in Washington, D.C., U.S., Aug. 31, 2026. Evelyn Hockstein | Reuters President Donald Trump on Monday said he struck new drug pricing deals with nine drugmakers to voluntarily sell their medications for less, building on his…
Gilead Bixlenvo drug Courtesy: Gilead The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients, the company announced Thursday. The drug, marketed as Bixlenvo, is aimed at patients whose virus is already under control but who remain on complicated treatment regimens. It could also appeal…
We’re selling 10 shares of Eli Lilly at roughly $1,269 each. Following Wednesday’s trade, Jim Cramer’s Charitable Trust will own 80 shares of LLY, decreasing its weighting in the portfolio to 2.6% from 2.9%. We’re locking in big gains in pharma giant Eli Lilly as shares jump to a fresh record high on Wednesday. Healthcare…
My top 10 things to watch Tuesday, Aug. 18 1. Bonds are the story of the day. The relentlessness of this worldwide bond market rout is unnerving, pushing yields to decently attractive levels. We are not seeing any let up. Here at home, the 30-year Treasury yield is at a roughly two-decade high, at over…
Eli Lilly has won its first approval to sell its weight-loss drug Foundayo outside the U.S., allowing it to compete with rival Novo Nordisk’s Wegovy pill in the U.K. It marks only the second GLP-1 weight-loss pill in the European market and comes just two months after Novo launched its Wegovy pill there. The U.K.’s…
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of two GLP-1 drugmakers were on full display this week. Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly’s results, sending shares higher on Wednesday, they punished Novo…
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma’s increasing embrace of a long-stigmatized class of medications as alternatives for treating an array of mental health…
